New Nanomicellar Form of Latanoprost 0,005 % in Treatment Open Angle Glaucoma-Reference-Cited by-同舟云学术

New Nanomicellar Form of Latanoprost 0,005 % in Treatment Open Angle Glaucoma

Published:2024-06-28 Issue:2 Volume:21 Page:375-385
ISSN:2500-0845
Container-title:Ophthalmology in Russia
language:
Short-container-title:Oftalʹmologiâ

Author:

Dukhanin A. S.¹^ORCID,Zagidullina A. Sh.²^ORCID,Azamatova G. A.³^ORCID

Affiliation:

1. N.I. Pirogov Russian National Research Medical University

2. Bashkir State Medical University

3. Bashkir State Medical University; Branch of Clinic Bud Zdorov

Abstract

This article provides a review of Lanpressun®, a new formulations of latanoprost micellar nanoemulsion without benzaltonium chloride (BAK). The pharmacokinetics and pharmacodynamics of new formulations are presented. Due to innovative delivery system and absence of detergent preseravative (BAK, poliquaternium and others) Lanpressun® possess better tolerability and safety to ocular surface, that provides patients adherence to longer therapy. The article presents the results of clinical trials demonstrating high hypotensive efficacy of Lanpressun®. Literature analysis of studies on safety and effect on ocular surface shows good tolerability of preservativefree latanoprost nanoemulsion. The authors give the assessment of Lanpressun® future perspectives in treatment of patients with openangle glaucoma

Publisher

PE Polunina Elizareta Gennadievna

Reference44 articles.

1. Aznabaev BM, Zagidullina ASh, Fakhretdinova EV, Arslanova AI. Primary disability caused by glaucoma in the Republic of Bashkortostan in 2014–2019. National Journal glaucoma. 2021;20(1):39–46 (In Russ.). doi: 10.25700/NJG.2021.01.05.

2. Aznabaev BM, Zagidullina ASh, Arslanova AI. Disability caused by glaucoma in the Republic of Bashkortostan in the years 2014–2019. National Journal glaucoma. 2021;20(2):44–50 (In Russ.). doi: 10.53432/2078-4104-2021-20-2-44-50.

3. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and metaanalysis. Lancet Glob Health. 2017 Dec;5(12):e1221–e1234. doi: 10.1016/S2214109X(17)30393-5.

4. Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, Herndon LW Jr, Lim MC, Williams RD. Primary Open‑Angle Glaucoma Preferred Practice Pattern(®) Guidelines. Ophthalmology. 2016 Jan;123(1):P41–P111. doi: 10.1016/j.ophtha.2015.10.053.

5. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144–e160. doi: 10.1016/S2214109X(20)30489‑7.